WO2004082601A3 - Methode de traitement du diabete et maladies liees au diabete - Google Patents

Methode de traitement du diabete et maladies liees au diabete Download PDF

Info

Publication number
WO2004082601A3
WO2004082601A3 PCT/US2004/006906 US2004006906W WO2004082601A3 WO 2004082601 A3 WO2004082601 A3 WO 2004082601A3 US 2004006906 W US2004006906 W US 2004006906W WO 2004082601 A3 WO2004082601 A3 WO 2004082601A3
Authority
WO
WIPO (PCT)
Prior art keywords
diabetes
related disorders
levels
relates
treating
Prior art date
Application number
PCT/US2004/006906
Other languages
English (en)
Other versions
WO2004082601A2 (fr
Inventor
James N Livingston
Manami Tsutsumi
Original Assignee
Bayer Pharmaceuticals Corp
James N Livingston
Manami Tsutsumi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp, James N Livingston, Manami Tsutsumi filed Critical Bayer Pharmaceuticals Corp
Publication of WO2004082601A2 publication Critical patent/WO2004082601A2/fr
Publication of WO2004082601A3 publication Critical patent/WO2004082601A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Cette invention porte sur une méthode de traitement du diabète et des maladies liées au diabète. La méthode de cette invention consiste notamment à administrer un composé unique qui réduit les taux de glucose dans le sang, ainsi que les taux de triglycéride sérique et augmente les taux de lipoprotéines sériques de haute densité (HDL), ce qui entraîne éventuellement le traitement d'individus soufrant d'un trouble métabolique tel que le diabète sucré, la résistance à l'insuline, la diminution de tolérance au glucose et la dyslipidémie.
PCT/US2004/006906 2003-03-13 2004-03-05 Methode de traitement du diabete et maladies liees au diabete WO2004082601A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45428103P 2003-03-13 2003-03-13
US60/454,281 2003-03-13

Publications (2)

Publication Number Publication Date
WO2004082601A2 WO2004082601A2 (fr) 2004-09-30
WO2004082601A3 true WO2004082601A3 (fr) 2005-03-10

Family

ID=33029869

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/006906 WO2004082601A2 (fr) 2003-03-13 2004-03-05 Methode de traitement du diabete et maladies liees au diabete

Country Status (1)

Country Link
WO (1) WO2004082601A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1630152A4 (fr) * 2003-05-30 2009-09-23 Takeda Pharmaceutical Compose cyclique condense
WO2014165816A1 (fr) * 2013-04-05 2014-10-09 North Carolina Central University Composés utiles dans le traitement de troubles métaboliques et leur synthèse

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6028052A (en) * 1995-09-18 2000-02-22 Ligand Pharmaceuticals Incorporated Treating NIDDM with RXR agonists

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6028052A (en) * 1995-09-18 2000-02-22 Ligand Pharmaceuticals Incorporated Treating NIDDM with RXR agonists

Also Published As

Publication number Publication date
WO2004082601A2 (fr) 2004-09-30

Similar Documents

Publication Publication Date Title
WO2004052284A3 (fr) Traitement de diabetes
Vardarli et al. Effects of sitagliptin and metformin treatment on incretin hormone and insulin secretory responses to oral and “isoglycemic” intravenous glucose
WO2006034435A3 (fr) Methodes et composition permettant de traiter les affections associees au glucose, le syndrome metabolique, les dyslipidemies et d'autres affections
WO2004028469A3 (fr) Regulation glycemique amelioree dans le prediabete et/ou le diabete de type ii au moyen de l'acide docosahexaenoique
WO2011112822A8 (fr) Dispositif thérapeutique implantable et procédés de fabrication
Schiaffini et al. The Continuous Glucose Monitoring System (CGMS) in type 1 diabetic children is the way to reduce hypoglycemic risk
MX2011008416A (es) Medicaciones antidiabeticas que comprenden un inhibidor de dpp-4 (linagliptina) opcionalmente en combinacion con otros antidiabeticos.
WO2010049678A3 (fr) Traitement de maladies utilisant de l’énergie
EA200900896A1 (ru) Соединения-агонисты гетероциклических рецепторов (варианты), фармацевтическая композиция на их основе, способ лечения диабета и метаболических расстройств, способ стимулирования выработки инсулина (варианты) и способы снижения уровня глюкозы и триглицеридов в крови посредством указанных соединений
AU2002327430A8 (en) Methods for treating diabetes and other blood sugar disorders
WO2005023081A3 (fr) Controle du niveau de glucose dans le sang
WO2005012485A3 (fr) Procedes pour traiter le diabete, et les troubles associes, au moyen d'inhibiteurs des pde10a
WO2006044531A3 (fr) Modulation antisens de l'expression de ptp1b
WO2000073331A3 (fr) Utilisation d'exendines et de leurs agonistes pour le traitement du diabete sucre gestationnel
WO2005027839A3 (fr) Procedes et reactifs pour le traitement des troubles immuno-inflammatoires
WO2004050115A3 (fr) Polytherapie mettant en oeuvre des exendines et des thiazolidinediones
WO2004021858A3 (fr) Controle du niveau de glucose dans le sang
WO2005087310A3 (fr) Procedes et appareils gastro-intestinaux destines a etre utilises dans le traitement des troubles et le controle de glycemie
SG161234A1 (en) A method and composition for nutritionally improving glucose control and insulin action
Gupta et al. Oral zinc therapy in diabetic neuropathy.
BR0311161A (pt) Método de tratamento de diabetes
WO2006007400A9 (fr) Procedes de diagnostic et de traitement de l'obesite, du diabete et de la resistance a l'insuline
WO2006138372A3 (fr) Procedes et reactifs pour le traitement de troubles inflammatoires
Strasser Diagnostic criteria of cachexia and their assessment: decreased muscle strength and fatigue
EP1634605A3 (fr) traitement de la dyslipidémie chez un patient souffrant de diabète de type 2

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
122 Ep: pct application non-entry in european phase